Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations.
about
Microbiota transplantation: concept, methodology and strategy for its modernization.Radiation and PD-(L)1 treatment combinations: immune response and dose optimization via a predictive systems model.Immune Checkpoint Inhibitors to Treat Malignant Lymphomas.The association of human endogenous retrovirus-H long terminal repeat-associating protein 2 (HHLA2) expression with gastric cancer prognosis.Immune oncology, immune responsiveness and the theory of everything.Advances in immuno-oncology biomarkers for gastroesophageal cancer: Programmed death ligand 1, microsatellite instability, and beyond.Is high serum programmed death ligand 1 level a risk factor for poor survival in patients with gastric cancer?CTLA-4 and PD-1 Ligand Gene Expression in Epithelial Thyroid CancersThe intracellular signalosome of PD-L1 in cancer cellsImmunotherapy combined with epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer treatmentImmune Checkpoints as Therapeutic Targets in AutoimmunityIn tumor cells, thyroid hormone analogues non-immunologically regulate PD-L1 and PD-1 accumulation that is anti-apoptotic2018 Nobel Prize in physiology or medicinePretreatment hematological markers predict clinical outcome in cancer patients receiving immune checkpoint inhibitors: A meta-analysisAre Long-Chain Polyunsaturated Fatty Acids the Link between the Immune System and the Microbiome towards Modulating Cancer?Enhancement of Antitumor Vaccination by Targeting Dendritic Cell-Related IL-10Immune-related adverse events of immune checkpoint inhibitors: a brief review
P2860
Q52716963-3F45EFC2-F063-47D5-AB48-A233F997EB87Q55040614-AACA5065-B642-4DF9-8925-90F3E84B9093Q55106038-C969D624-09FA-4074-978A-D650652EF057Q55240839-F12698E1-58D8-4EA1-A001-831DABE688C1Q55487467-6A852FF8-D124-477C-A3BF-DE61D9CF2462Q55506755-73E9CE37-0D78-4C67-AA6A-0301526841B8Q55554723-CB89700A-B4EA-4F9A-941E-F30511810C9DQ56891239-7929229B-F574-467D-AE4D-0ED43D2321EFQ57067759-0F06D9A9-C236-4871-B348-3C47A6FDA552Q57069991-58A3117B-5122-4067-822F-762CE0F35A34Q57817465-CEBE63F8-95F3-4368-BE58-6455FB9320B0Q57821568-8533397B-FF74-47BF-8653-AD7B9488BD55Q58565746-DBA190E7-209F-4D82-A156-4DA71057C159Q58700048-C470E2B4-23A0-4548-9C0E-78ABE5B83F84Q58753378-CA8092F1-EF54-4DD9-9E72-6571413223A1Q58767527-A149DE8C-19D6-4966-B67A-4C9D87EEC3F3Q59126189-4863F23D-15AF-4371-BEF2-4F39E88198B0
P2860
Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations.
description
2018 nî lūn-bûn
@nan
2018年の論文
@ja
2018年学术文章
@wuu
2018年学术文章
@zh-cn
2018年学术文章
@zh-hans
2018年学术文章
@zh-my
2018年学术文章
@zh-sg
2018年學術文章
@yue
2018年學術文章
@zh
2018年學術文章
@zh-hant
name
Development of PD-1 and PD-L1 ...... als and future considerations.
@en
Development of PD-1 and PD-L1 ...... als and future considerations.
@nl
type
label
Development of PD-1 and PD-L1 ...... als and future considerations.
@en
Development of PD-1 and PD-L1 ...... als and future considerations.
@nl
prefLabel
Development of PD-1 and PD-L1 ...... als and future considerations.
@en
Development of PD-1 and PD-L1 ...... als and future considerations.
@nl
P2093
P2860
P921
P1476
Development of PD-1 and PD-L1 ...... als and future considerations.
@en
P2093
Alexander Chehrazi-Raffle
Srikanth Reddi
P2860
P2888
P356
10.1186/S40425-018-0316-Z
P50
P577
2018-01-23T00:00:00Z
P6179
1100559771